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Summary 
CD30 is a member of the tumor necrosis factor receptor superfamily and a surface marker for 
Hodgkin's disease.  Normal activated T  cells and several virally transformed T  or B  cell lines 
also show CD30 expression. The interaction of CD30 with its ligand induces cell death or pro- 
hferation, depending on the cell type. In this report we characterize the signals mediated by the 
intracellular domain of CD30 and show that, in combination with signal(s) transduced by the T 
cell receptor, the multimerization of CD30 cytoplasmic domain induces Fas(CD95)-indepen- 
dent cell death in  T  cell hybridomas. Deletion analysis  shows  that  the  COOH-terminal  66 
amino acids of CD30 are required to induce cell death. Using the yeast two-hybrid system, we 
have identified that the same region of CD30  interacts with tumor necrosis factor receptor- 
associated factor (TKAF)I  and TRAF2.  These results indicate that TKAF1  and/or TRAF2 
play an important role in cell death in addition to their previously identified roles in cell prolif- 
eration. 
C 
D30  is  a  member of the  TNF/nerve growth  factor 
(NGF) receptor superfamily which includes TNF-R1, 
TNF-R2,  the low affinity NGF  receptor, CD40,  CD27, 
Fas, 4-1BB, and OX40 (1-10). All of these cell surface re- 
ceptors show similarity characterized by repeating cysteine- 
rich motifs in  their extracellular domains.  The expression 
of these receptors is tightly regulated during activation and 
differentiation. For example, the expression of these recep- 
tors  is  upregnlated  upon  antigen  specific activation of T 
cells.  The interaction of these receptors with their respec- 
tive ligands induces cell death or proliferation, depending 
on the cell type (1-5,  10,  11).  Despite their diverse effects 
on cells, the signaling processes of these receptors are only 
beginning to be unveiled. In contrast to their extracellular 
domains,  the cytoplasmic domains of these receptors con- 
tain no significant homology within the superfamily or to 
other known proteins, suggesting that they may use distinct 
signaling pathways. 
Three members of the TNF family (TNF-1K1, Fas, and 
CD30)  have been shown to induce cell death upon their 
interaction with their hgands  (1-3,  12).  A  region of weak 
homology has  recently been identified between the cyto- 
plasmic domains of TNF-1K1 and Fas (13, 14). This region, 
now referred to as the death domain, is required for the in- 
duction of cell death by these receptors. Proteins interact- 
ing with  the  cytoplasmic domains  of these  receptors also 
contain  similar  death  domains  (15-17).  However,  CD30 
does not possess  the  death domain in its  cytoplasmic do- 
main,  despite  the  fact  that  interaction  of CD30  with  its 
ligand  induces  cell  death  in  certain  cells,  suggesting  that 
CD30 uses  a different signaling pathway for cell death in- 
duction. 
In this report we characterize the signals mediated by the 
intracellular  domain  of CD30  and  show  that  the  mul- 
timerization of the CD30 cytoplasmic domain, in combi- 
nation with a concomitant signal(s) via the TC1K, induces 
Fas(CD95)-independent cell death ofT cell hybridomas. De- 
letion analysis  shows  that  the  COOH-terminal  66  amino 
acids of CD30 are required to induce cell death. Using the 
yeast two-hybrid system, we have identified that the same 
region  of CD30  interacts  with  TNFIK-associated  factor 
(TKAF)I and TRAF2  (18).  These results  strongly suggest 
that TRAF1 and/or TRAF2 are involved in CD30-medi- 
ated cell death induction in T  cell hybridomas. 
Materials and Methods 
Construction of Chimeric Receptors.  The extracellular and trans- 
membrane portion of CD8~ (residues 1-187; 19) were amphfied 
by PCR from pMV7F1.2  (kindly provided by Dr. Dan Littman, 
The Skirball Institute,  New York University,  New York,  NY) 
with  primers  5'CD8  (5'-CGCGTCGACATGGCCTTACCA- 
GTG-3')  and  3'CD8  (5'-ACGTCTTGAATTCCTGTGGTT- 
GCA-3').  The amplified fragments were  cloned into  SalI and 
EcoR.I sites ofpBluescript (Strategene Inc., La Jolla, CA) to give 
pCD8Ext. Cloning of foreign cDNA into the EcoRI site at the 
3'  end of CD8 in pCD8Ext will give in-frame fusion proteins. 
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GGATTC-3') and 3'CD30 (5'-AGAGGATTCAGCCCAGGC- 
CTCACTTTCCAGAGG-3') primers were used to amplify the 
cytoplasmic domain of CD30  (amino acid residues 408-595;  4) 
from the  cDNA of activated peripheral T  cells.  Similarly, chi- 
meric  receptors with  COOH-terminal  deletions of the  CD30 
cytoplasmic domain  were  made  using  different  3'  primers,  5'- 
GCAGGATTCTCACAGTGGCTGGCTCATTAACCC-3'  for 
CD30(-127)  and 5'-AGCGGATCCTCACCCCACGATCAC- 
GGTGTCAGC-3'  for  CD30(-66).  Fas  cytoplasmic  domain 
(amino acid residues 177-319;  20)  was also obtained by PCIK. 
The  amplified fragments were  cloned into  pBluescript and se- 
quenced.  Fragments with  correct  sequences  were  inserted  in- 
frame into the EcolKI site of pCD8Ext.  The resulting chimeric 
receptors and wild-type CD8 were excised from the plasmid and 
ligated into the XhoI and BamHI sites of the retroviral expression 
vector, pLXSN, for transfection experiments (21). 
Transfection and Retroviral Infection.  The retroviral vectors ex- 
pressing wild type CD8  (CD8)  and  chimeric receptors  (CD8/ 
CD30, CD8/C2, CD8/C4, and CD8/Fas) were transiently trans- 
fected into  a  packaging cell line, BOSC-23,  as previously de- 
scribed (22). 2 d after transfection, recombinant viruses were col- 
lected and used to infect the T  cell hybridomas KMIs-8.3.5 or 
KCIT1-8.5. Transfectants were selected by G418 resistance. The 
surface  expression  of CD8  and  chimeric  receptors  was  deter- 
mined by immunofluorescence analysis with OKT8  and FITC- 
conjugated goat anti-mouse Abs. The transfectants showing similar 
surface  expression of CD8  and chimeric receptors were isolated 
and  used  for  further  analysis.  For induction  of cell death,  the 
transfectants (5 X  104/well) were plated on 96-well plates coated 
with purified H57-597 (10 p,g/ml) and/or OKT8 (10 p,g/ml) for 
24 h.  The purified anti-Fas MAb Jo2  (PharMingen, San Diego, 
CA) was used at 1 p,g/ml. The production of IL-2 was measured 
as described previously (23).  Cell viability was measured by try- 
pan blue uptake. The percentage of cell viability indicated is the 
number of live cells per total cell number in the well. All are rep- 
resented as an average of at least three different experiments. 
Interaction of CD30 Cytoplasmic Domain with TRAF1 and TRAF2. 
PC1K was used to obtain the entire cytoplasmic domain or differ- 
ent deletions of CD30 as described in Fig 1. Fragments with cor- 
rect sequences were  fused in-frame to  glutathione S-transferase 
(GST) by cloning into the EcoRI and NotI sites ofpGEX-5X-1 
(Pharmacia Inc., Piscataway, NJ). The plasmids were transformed 
into Escherichia coli XL-1  blue  (Strategene Inc.). Protein induc- 
tion, purification, and coprecipitation experiments were done es- 
sentially as described previously (24).  For coprecipitation experi- 
ments  in  293  cells,  pH[3actin-l-neo  plasmids  expressing  the 
epitope tagged TRAF1  (12CA5  epitope; 25)  or TRAF2  (1D4 
epitope; 26)  and  the  eukaryotic GST  expression vector pEBG 
(kindly provided by Dr. E. Spanopoulou, The Rockefeller Uni- 
versity)  expressing GST-CD30  or  GST  were  cotransfected  in 
various combinations as indicated in Fig. 3 b. Approximately 24 h 
after transfection, the cells were lysed, and lysates were subjected 
to purification with glutathione beads (24). Purified proteins were 
analyzed by Western blot analysis with mAbs 12CA5 and 1D4 as 
described  (25,  26).  For in  vitro  association experiments,  full- 
length murine TRAF1  and TRAF2 cDNA in pBluescript were 
transcribed and translated in vitro using the TNT|  reticu- 
locytes system (Promega Corp., Madison, WI)  with 3SS-labeled 
methionine.  Equal  amounts  of in  vitro-translated TKAF1  or 
TKAF2 were incubated in binding buffer (PBS containing 0.1% 
NP-40,  0.5  mM  dithiothreitol, 10%  glycerol, 1 mM  PMSF,  2 
Ixg/ml aprotinin) with ,--d  p~g of fusion protein bound to  glu- 
tathione beads for 45  rain at 4~  After washing five times with 
binding buffer, the proteins were eluted by boiling in SDS sample 
buffer for 5 rain and subsequendy analyzed by SDS-PAGE. 
Northern Blot A~lysis.  2 ~,g ofpoly(A)  + RNA, purified from 
unstimulated and stimulated KMls-8.3.5 T  cell hybridoma, was 
analyzed by Northern blot analysis as described (23).  Cells were 
stimulated with anti-TCIK Ab (on plates coated with 10 p~g/ml 
H57-597 overnight) for 4-6 h (23). 2.1-kb mlKNA was detected 
by hybridization with TRAF1 cDNA probe, and 2.2-kb mR.NA 
was detected with TKAF2 cDNA probe as previously described 
(18).  After analysis,  the filter was washed and rehybridized with 
glyceraldehyde  phosphate  dehydrogenase  (GAPDH)  probe  to 
control for the amount of mlKNA loaded as described (23). 
Results  and  Discussion 
TCR-dependent  Cell Death of T  Cell Hybridomas Mediated 
by Multimerization of CD30 Cytoplasmic  Domains.  Recep- 
tor multimerization is a common signal transduction mech- 
anism in the  TNF  receptor superfamily (1-3).  Therefore, 
we  have  analyzed  the  signaling  processes  mediated  by 
CD30  with  a  chimeric  receptor  (CD8/CD30)  that  links 
the  extracellular and  transmembrane  domains  of CD8  to 
the  cytoplasmic domain  of CD30  (4,  19)  (Fig.  1).  Either 
the  chimeric  receptor  or  wild-type CD8  was  transfected 
into  the  T  cell hybridoma  KMls-8.3.5.  Transfectants  ex- 
pressing similar surface receptors were  selected by immu- 
nofluorescence  analysis  with  the  anti-CD8  (Ab)  OKT8 
(data  not  shown).  OKT8  treatment  of CD8 + or  CD8/ 
CD30 + transfectants changed neither IL-2 production nor 
cell viability. Treatment with anti-TC1K Ab (H57-597)  in- 
duced significant cell death in both  transfectants as previ- 
ously described (23).  Combined  treatment with  H57-597 
and OKT8 resulted in a similar degree of cell death (Fig. 2 
a). OKT8 did not affect IL-2 production induced by H57- 
597  (data not shown). 
CD8 +  and  CD8/CD30 §  transfectants  incubated  with 
both H57-597  and Jo2  (an anti-Fas Ab; 27)  showed partial 
inhibition  of TCR-mediated  cell death  as previously de- 
scribed (28), suggesting that the anti-TCR Ab-induced cell 
death  was  mediated via  Fas(CD95)  (Fig.  2  a).  However, 
when  both  transfectants  were  treated  with  H57-597, 
OKTS,  and Jo2,  cell death  of CD8/CD30 +  transfectants 
was  not inhibited by Jo2,  whereas that of CD8 +  transfec- 
tants was  (Fig. 2  a). Similar results were also obtained with 
EXT  TM  CYT  chimeric receptors 
,~, CD8  CD8/CD8 
CD8  i  i CD30  CDS/CD30 
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r///////////////////~a Fas  CD8/Fas 
Figure 1.  Construction of various chimeric receptors. The extraceUular 
and transmembrane portions of CD8~ were fused to the various regions 
of the  CD30  or Fas cytoplasmic domain.  CD30,  the  entire region of 
CD30 cytoplasmic domain; CD30(-66), deletion of the COOH-termi- 
nal  66  amino  acid residues of CD30; CD30(-127),  deletion  of the 
COOH-terminal 127 amino acid residues of CD30; Fas, the entire Fas 
cytoplasmic domain. The resulting chimeric receptors are designated as 
CD8/CD30,  CD8/C4, CD8/C2, and CD8/Fas on the right. 
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Figure 2.  (a) Combined treatment with and-TCR and anti-CD8 Abs 
induces cell death of the CD8/CD30 + KMIs-8.3.5  transfectants,  which is 
not blocked by the addition ofand-Fas Ab. The wild-type CD8 + KMIs- 
8.3.5 transfectants  are indicated  as K8/CD8.5 and K8/CD8.6. The CD8/ 
CD30  + KMls-8.3.5 transfectants  are K8/CD8/30.2 and K8/CD8/30.12. 
The transfectants  were treated with the Abs indicated in the legend: H57 
(anti-TCR Ab, H57-597), OKT8 (anti-CD8 Ab),  Jo2 (anti-Fas  Ab), and 
FBS (fetal bovine serum). Cell viability  was determined after 24 h by try- 
pan blue uptake. (b) Both anti-TCR and anti-CD8 Abs are required to 
induce cell death in CDS/CD30 + KCIT1-8.5 transfectants.  Transfectants 
expressing CD8/Fas undergo cell death by the treatment of anti-CD8 Ab 
alone. CD8 § KCIT1-8.5 transfectants are indicated as KC/CD8.1  and 
KC/CD8.4.  The CD8/CD30 + KCIT1-8.5 transfectants  are KC/CD8/ 
30.4, KC/CD8/30.6,  and KC/CD8/30.11.  The CD8/Fas  + KCIT1-8.5 
transfectants are KC/CD8/FAS.2, KC/CD8/FAS.6, and KC/CD8/FAS.8. 
Ab treatments  of the transfectants  are indicated on the legend: H57 (anti- 
TCtL Ab, H57-597), OKT8 (anti-CD8 Ab), and FBS (fetal bovine se- 
rum). Cell viability  was determined after 24 h. (c) The COOH-terminal 
66 amino acid residues of CD30 are required for the induction of cell 
death. The KCIT1-8.5 transfectants  expressing  CD8/C2  (deletion of the 
COOH-terminal  127  amino acid residues) are  KC/CD8/C2.3,  KC/ 
CD8/C2.7, and KC/CD8/C2.11.  The KCIT1-8.5 transfectants  express- 
another T  cell hybridoma, DOl1-10/$4.4 (data not shown), 
demonstrating that multimerization of both the CD30 cy- 
toplasmic domain and the TCtL transduced a cell death sig- 
nal that is independent of Fas.  This Fas independence was 
confirmed by transfection experiments in the T  cell hybri- 
doma  KCIT1-8.5,  which  does  not  undergo  cell  death 
upon TCtL cross-linking due to  deficient Fas(CD95)  ex- 
pression (Park,  C.G.,  S.Y.  Lee,  and Y.  Choi,  manuscript 
submitted for publication). As shown in Fig. 2 b, combined 
treatment  with  H57-597  and  OKT8  induced significant 
cell death ofCD8/CD30 + KCIT1-8.5 transfectants, which 
was not affected by the addition of Jo2  (data not shown). 
To determine the functional regions within the CD30 cy- 
toplasmic domain responsible for induction of cell death, 
further  transfection  experiments  were  performed  with 
CD8/CD30-chimeric receptors  encoding COOH-termi- 
hal deletions of CD30 (Fig. 1); the results indicate that the 
COOH-terminal 66 amino acids of CD30 are required to 
induce cell death (Fig. 2 c). 
These results establish that multimerization of CD30 cy- 
toplasmic domains in T  cell hybridomas induces cell death, 
similar to what has been observed in certain other cell lines 
(1-3, 5,  11). The CD30-mediated cell death ofT  cell hy- 
bridomas, however, requires a concomitant signal(s) via the 
TCR, which differs from the TCR.-independent cell death 
induced by  multimerization of Fas  cytoplasmic  domains 
(Fig. 2 b). 
TRAF1  and  TRAF2  Are  Involved  in  the  Death-signaling 
Processes via CD30.  It has been previously reported  that 
the cytoplasmic region of Fas(CD95)  contains a death do- 
main, crucial for cell death induction, that  mediates pro- 
tein-protein interactions with  other  death  domain-con- 
taining signal transducers (12,  13,  16,  17).  The cytoplasmic 
domain of CD30 does not have an apparent death domain, 
suggesting that different signaling processes are responsible 
for  cell  death  induction. To  further  characterize  the  cell 
death-signaling processes mediated by CD30, we used the 
yeast  two-hybrid  system  (29)  and  identified  two  clones 
(clones 9  and 35) that interact specifically and equally well 
with the  cytoplasmic domain of CD30  (data not shown). 
Sequence analysis of cDNAs of these  clones revealed that 
clone 9 contained amino acid residues 204--409 of TRAF1, 
and  clone  35  contained amino acid  residues  241-501  of 
T1LAF2, which were previously identified by their associa- 
tion  with  p75  TNF  receptor  (TNF-R2)  (18;  data  not 
shown). 
The specific interaction of TRAF1 and TRAF2 with the 
CD30 cytoplasmic domain was confirmed by coprecipita- 
tion experiments using a series of GST fusion proteins with 
the cytoplasmic domain of CD30 and other cell surface re- 
ceptors as controls. Both TRAF1 and TRAF2 were copre- 
cipitated with GST-CD30 after coexpression in 293  cells 
ing CD8/C4 (deletion of the COOH-terminal 66 amino acid residues) 
are KC/CD8/C4.1,  KC/CD8/C4.6,  and KC/CD8/C4.8.  The transfec- 
tants were treated with the Abs indicated on the legend: H57 (anti-TCR 
Ab, H57-597). OKT8 (anti-CD8 Ab), and FBS (fetal  bovine serum). Cell 
viability  was determined after 24 h. 
671  Lee et al.  Brief Definitive Report Figure 3.  The cytoplasmic  domain of CD30 interacts with TRAF1 and TRAF2. (a) GST fusion proteins containing various portions of  the CD30 cy- 
toplasmic domain. The GST fusion proteins with COOH-terminal deletions of CD30 are C3 (deletion of  the COOH-termina197  residues)  and C4 (de- 
letion of the COOH-terminal 66 residues).  The GST fusion proteins with NH2-terminal deletions of the CD30 cytoplasmic  domain are N1 (deletion of 
the NH2-terminal 28 residues), N2 (deletion of the NH2-terminal 61 residues), N3 (deletion of the NH2-terminal 91 residues, and N4 (deletion of the 
NH2-terminal 121 residues). Amino acid residue numbers of CD30 are also indicated. (b) Coprecipitation of TRAF-1 and TRAF-2 by GST--CD30 in 
293 cell extracts. (c and a') Association  of  in vitro translated  TRAF1 or TRAF2 with GST-CD30.  The COOH-termina166  amino acid residues of CD30 
are sufficient to interact with TRAF1 and TRAF2. Different deletions of the CD30 cytoplasmic domain are described in a. In vitro-translated TRAF1 
and TRAF2 products before the coprecipitation experiments are indicated as TRAF1 and TRAF2, respectively. TRAF1 and TRAF2 are marked with 
arrows. GST-FAS, GST fusion protein with the Fas cytoplasmic  domain. 
(Fig. 3  b).  In vitro-translated TRAF1  and TRAF2 showed 
independent binding to GST-CD30  (Fig. 3, c and d). Nei- 
ther TRAF1 nor TRAF2 bound to GST or GST-Fas (Fig. 
3. c and d). 
Further experiments with a series of NH2- and COOH- 
terminal deletion mutants  of CD30  showed that the  same 
COOH-terminal  66  amino  acid residues of CD30  neces- 
sary for  cell death  induction  are  su~cient  for  interaction 
with either TRAF1  or TRAF2  (Fig. 3, c and d). This cor- 
relation strongly suggests that TRAF1  and/or TRAF2  are 
involved in the CD30-mediated cell death of T  cell hybri- 
domas described above. Interestingly, although TRAF2 ex- 
pression was not significantly altered, the level of TRAF1 
mRNA  was  dramatically increased  in  T  cell hybridomas 
upon activation via the TCR  (Fig. 4). This raises the possi- 
Figure 4.  TtLAF1  expression in T 
cell hybridomas is dramatically up- 
regulated  upon  activation  via  the 
TCR.  Similar results were obtained 
with  RNA from  KCIT1-8.5  (data 
not shown), c, control unstimulated 
RNA; a, TCR-activated RNA. 
bility that  the  upregulation of TRAF1  expression may be 
part  of the  TCR-mediated  signal(s)  required  for  CD30- 
mediated cell death induction described above. Future ex- 
periments with dominant-negative forms of TRAF proteins 
are  required to  show whether  TRAF  proteins are  indeed 
mediating signals for observed cell death. 
TRAF1, TRAF2, and other TRAF proteins were previ- 
ously  shown  to  interact  with  TNF-R2,  CD40,  and  the 
EBV transforming protein LMP1, all of which play impor- 
tant roles in cell proliferation (18, 30-32).  The results pre- 
sented here show that TR.AF1 and/or TRAF2 also interact 
with  CD30.  However,  the  interaction  of TRAF  proteins 
with  CD30  appears  to  induce  cell death  rather  than  cell 
proliferation ofT  cell hybridomas. Since CD30 directly in- 
teracts with either TRAF1  or TRAF2,  whereas TNF-R2 
interacts with TRAF1  indirectly via TRAF2  (18),  it sug- 
gests  that  the  manner  by  which  TRAF  proteins  interact 
with  cognate  cell surface receptors may result in  different 
effects on cells. However, it is also equally possible that dif- 
ferent outcomes of TRAF-mediated signals, cell prolifera- 
tion or death, may be dependent on cell type rather than its 
cognate cell surface receptors. 
Fas has been shown to be a key molecule in maintaining 
peripheral T  cell tolerance.  However,  the  negative  selec- 
tion  of immature  thymocytes  is  not  affected  in  Fas-defi- 
cient  mice,  suggesting  that  a  Fas-independent  pathway 
must  operate  in  the  clonal  deletion  of self-reactive  thy- 
mocytes (12).  The  result that cell death induced by TCR 
and CD30  is independent  of Fas suggests that  CD30  may 
play an important role during negative selection of imma- 
ture thyrnocytes. 
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